Medina Manuel Hidalgo Sells 1,700 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,700 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $164.24, for a total value of $279,208.00. Following the sale, the director owned 4,556 shares in the company, valued at approximately $748,277.44. The trade was a 27.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Thursday, May 28th, Medina Manuel Hidalgo sold 1,000 shares of Guardant Health stock. The stock was sold at an average price of $130.06, for a total value of $130,060.00.
• On Wednesday, May 20th, Medina Manuel Hidalgo sold 1,250 shares of Guardant Health stock. The stock was sold at an average price of $107.09, for a total value of $133,862.50.

Guardant Health Stock Performance

Shares of GH opened at $168.48 on Friday. Guardant Health, Inc. has a 52-week low of $51.44 and a 52-week high of $176.58. The business’s 50 day moving average price is $147.02 and its two-hundred day moving average price is $115.20. The firm has a market cap of $22.61 billion, a PE ratio of -48.27 and a beta of 1.60.

Hedge Funds Weigh In On Guardant Health

Several large investors have recently added to or reduced their stakes in GH. V Square Quantitative Management LLC bought a new stake in Guardant Health during the 4th quarter worth approximately $27,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Guardant Health in the fourth quarter valued at approximately $31,000. Elyxium Wealth LLC purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $35,000. Parallel Advisors LLC boosted its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new position in shares of Guardant Health during the second quarter valued at approximately $59,000. Institutional investors own 92.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GH. Royal Bank Of Canada increased their target price on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Sanford C. Bernstein lifted their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday, July 2nd. Evercore reaffirmed an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. Wolfe Research assumed coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective on the stock. Finally, Bank of America increased their price objective on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.